Sunshine Biopharma Upgrades COVID-19 Provisional Patent Application to Full PCT Application streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
RB Capital Increases Investment in Sunshine Biopharma
April 22, 2021 08:00 ET | Source: Sunshine Biopharma Inc. Sunshine Biopharma Inc. Montreal, Quebec, CANADA
MONTREAL, April 22, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that RB Capital has injected an additional investment of $500,000 to augment the Company’s Coronavirus drug development program. In addition, RB Capital has provided the Company with assurances that it will continue to provide funding over the next 30 days for the Company’s other R&D activities, including Ada-27a anticancer drug.
Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are very pleased to continue our relationship with RB Capital as long-term investor in the Company. They truly understand our vision and are prepared to help us
email article
The FDA will conduct an unprecedented public review of accelerated approval for oncology-drug indications left dangling for lack of confirmatory evidence to support benefits observed in earlier studies.
Beginning at 1 p.m. ET on Tuesday and continuing through Thursday, the FDA Oncologic Drugs Advisory Committee (ODAC) will hear evidence supporting a total of six indications for three different immune checkpoint inhibitors: nivolumab (Opdivo), pembrolizumab (Keytruda), and atezolizumab (Tecentriq). The three-day review pertains to indications in breast, urothelial, gastric, and hepatocellular cancers.
After hearing presentations from FDA staff and the sponsors for the three drugs, the panel will vote whether to recommend for or against continued approval of each indication and whether additional studies should be conducted. Other approved indications for the drugs will not be affected by the ODAC recommendations nor will pending applications for other indicati
Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
1
1Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
2Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, United States
3Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, United States
4Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, United States
Tumor-stromal interactions within the tumor microenvironment (TME) influence lung cancer progression and response to therapeutic interventions, yet traditional
in vitro studies fail to replicate the complexity of these interactions. Herein, we developed three-dimensional (3D) lung tumor models that mimic the human TME and demonstrate tumor-stromal crosstalk mediated by extracellular vesicles (EVs). EVs released by tumor cells, independent of p53 status, and fibroblasts within the TME mediate